{
    "clinical_study": {
        "@rank": "79091", 
        "arm_group": [
            {
                "arm_group_label": "Atorvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Patients in the atorvastatin group receive 80 mg atorvastatin (2 x atorvastatin 40 mg tablets) once daily from 24 hours before to 48 hours after administration of contrast material."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients in the placebo group receive 2 placebo tablets once daily from 24 hours before to 48 hours after administration of contrast material."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to determine the efficacy of atorvastatin in the prevention of\n      contrast-induced nephropathy in patients undergoing computed tomography coronary\n      angiography. Investigators assume that atorvastatin is effective in this regard.\n      Investigators include patients referring for elective computed tomography coronary\n      angiography and allocate them to atorvastatin or placebo from 24 hours before to 48 hours\n      after administration of contrast material. Investigators then measure serum creatinine and\n      see if it is raised by \u2265 0.5 mg/dL or \u2265 25% of the baseline value."
        }, 
        "brief_title": "High Dose Atorvastatin for Preventing Contrast-induced Nephropathy", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Contrast-Induced Nephropathy", 
        "condition_browse": {
            "mesh_term": "Kidney Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients\n\n          -  candidate of elective computed tomography angiogram\n\n          -  willingness to participate\n\n        Exclusion Criteria:\n\n          -  unstable angina or myocardial infarction, cardiac arrhythmia, seizures, acute renal\n             failure, end-stage renal disease\n\n          -  unstable serum creatinine\n\n          -  unstable hemodynamic\n\n          -  intravascular administration of contrast material in the past month\n\n          -  using high dose atorvastatin in the past month,\n\n          -  known hypersensitivity to atorvastatin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02114346", 
            "org_study_id": "392353"
        }, 
        "intervention": [
            {
                "arm_group_label": "Atorvastatin", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Atorvastatin", 
                    "Placebo"
                ], 
                "description": "Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.", 
                "intervention_name": "0.9% sodium chloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Computed Tomography Angiogram", 
            "Side Effects", 
            "Contrast-Induced Nephropathy", 
            "Prevention"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Isfahan", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Alzahra Hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluating the Effect of High Dose Atorvastatin (80 mg/d) Comparing With Placebo in Preventing Contrast-induced Nephropathy in Patients Undergoing Computed Tomography Coronary Angiography", 
        "overall_official": {
            "affiliation": "Isfahan University of Medical Sciences", 
            "last_name": "Alireza Hajian, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Plasma creatinine level is measured at baseline and after 48 hours of contrast injection. Increase in plasma creatinine level \u2265 0.5 mg/dL or \u2265 25% of the baseline creatinine after 48 hours of contrast injection will be considered contrast induced nephropathy.", 
            "measure": "Plasma creatinine level", 
            "safety_issue": "No", 
            "time_frame": "up to 48h after contrast injection"
        }, 
        "reference": {
            "PMID": "22511942", 
            "citation": "Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One. 2012;7(4):e34450. doi: 10.1371/journal.pone.0034450. Epub 2012 Apr 12."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02114346"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Isfahan University of Medical Sciences", 
            "investigator_full_name": "Alireza Hajian Nejad", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Isfahan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isfahan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}